Acute Care Syndromic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type (Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Others), By Target (Bacteria, Viruses, Fungi, Parasites), By Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others), By End User (Hospitals, Clinical and Diagnostic Laboratories, Research and Academic Institutions, Others), By Region, Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 2.89 billion

CAGR (2023-2028)

5.56%

Fastest Growing Segment

Respiratory Disease Segment

Largest Market

Asia Pacific

Market Overview

Global Acute Care Syndromic Testing Market has valued at USD 2.89 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.56% through 2028. Acute Care Syndromic Testing Markets are diagnostic approach used in healthcare settings, particularly in emergency departments and acute care facilities, to rapidly identify and diagnose the cause of acute symptoms or conditions in patients. This approach involves the simultaneous testing of multiple pathogens (such as viruses, bacteria, and other microorganisms) that could be responsible for a patient's symptoms. The goal is to quickly narrow down the potential causes and guide appropriate treatment decisions. Acute care syndromic testing is especially important in situations where patients present with symptoms that could be attributed to various infectious agents. This testing strategy allows healthcare providers to make timely and informed decisions regarding patient care, isolation measures, and treatment options. It can be particularly valuable during disease outbreaks or pandemics, as it helps healthcare systems efficiently manage and respond to a large number of patients with similar symptoms. However, The specific types of tests used in acute care syndromic testing may include molecular assays (like polymerase chain reaction or PCR tests), rapid antigen tests, serological tests (looking for antibodies), and other diagnostic methods. The choice of tests depends on the suspected pathogens and the clinical context.

Key Market Drivers

Rise in Infectious Disease Outbreaks Propels The Market Growth

The rise in infectious disease outbreaks has a significant impact on driving the growth of the global acute care syndromic testing market. Infectious disease outbreaks create a heightened demand for rapid and accurate diagnostic solutions, and acute care syndromic testing addresses this need. Influenza is the most common infectious disease in the world, but some diseases are more prevalent than others. In the United States alone, about 1 in every 5 people gets the flu every year, but only about 300 people get prion disease each year. Acute care syndromic testing enables healthcare providers to quickly identify the pathogens responsible for the outbreak. Rapid diagnosis allows for early detection and timely implementation of containment measures, such as isolating infected individuals and implementing infection control protocols. During an outbreak, healthcare facilities experience an influx of patients with similar symptoms. Acute care syndromic testing streamlines patient management by providing a comprehensive assessment of the potential pathogens causing the outbreak, allowing for appropriate treatment and care planning. Identifying the causative agent of an outbreak promptly helps limit its spread within the community and healthcare settings. Acute care syndromic testing assists in identifying carriers, isolating cases, and preventing further transmission. Different infectious agents may require specific treatments. Acute care syndromic testing aids in tailoring treatment plans by providing information about the pathogens involved and their susceptibility to different therapies, which can lead to more effective patient outcomes. Outbreaks often strain healthcare resources. Acute care syndromic testing optimizes resource allocation by quickly identifying cases that require immediate attention and enabling efficient use of medical supplies, personnel, and facilities. Infectious disease outbreaks have highlighted the importance of global health security. Acute care syndromic testing is a critical tool in enhancing preparedness and response capabilities, ensuring a rapid and effective response to emerging threats.

The collective impact of these factors creates a strong demand for acute care syndromic testing solutions during infectious disease outbreaks. This demand, in turn, drives investment in research and development, technological advancements, and adoption of syndromic testing platforms, contributing to the growth of the global acute care syndromic testing market.

Increasing Demand for Timely Diagnostics Drives the Market Growth

The increasing demand for timely diagnostics plays a crucial role in driving the growth of the global acute care syndromic testing market. Timely diagnostics are essential for a range of medical conditions, especially in acute care settings, where rapid and accurate diagnosis can significantly impact patient outcomes. Here's how the demand for timely diagnostics contributes to the growth of the acute care syndromic testing market. In acute care settings, such as emergency departments, rapid and accurate diagnosis is essential for making urgent treatment decisions. Acute care syndromic testing provides a comprehensive analysis of potential pathogens, enabling healthcare providers to quickly identify the cause of symptoms and initiate appropriate treatment protocols. Acute care syndromic testing platforms are designed to provide quick results, often within a matter of hours. This rapid turnaround time is crucial for situations where immediate diagnosis is necessary to prevent disease progression or complications. Timely diagnostics help healthcare providers efficiently manage patients' conditions. Acute care syndromic testing aids in patient triage, isolation, and targeted interventions, allowing for optimal resource allocation and care planning. Traditional diagnostic methods can sometimes lead to delays due to laboratory processing times and sample transportation. Acute care syndromic testing reduces the risk of delays and backlogs, ensuring that patients receive timely diagnoses and treatments. Rapid diagnosis through acute care syndromic testing can lead to improved patient outcomes. Early initiation of appropriate therapies can reduce the severity of illness, lower mortality rates, and decrease the risk of complications.

Increased Adoption Of Point-Of-Care Testing Drives the Market Growth

The increased adoption of point-of-care (POC) testing significantly drives the growth of the global acute care syndromic testing market. Point-of-care testing refers to diagnostic testing that is performed at or near the patient's location, such as a hospital bedside, clinic, or other healthcare settings. Point-of-care testing provides immediate results, enabling healthcare providers to quickly diagnose patients' conditions and make timely treatment decisions. In acute care settings, where time is critical, rapid diagnosis through POC testing can lead to faster initiation of appropriate therapies. Traditional laboratory testing often involves sending samples to centralized labs, leading to longer turnaround times for results. POC testing eliminates the need for sample transportation and processing delays, ensuring that patients receive timely diagnoses. POC testing streamlines patient management by allowing healthcare providers to assess patients' conditions and determine appropriate treatments without waiting for lab results. This efficiency is especially valuable in acute care scenarios. With POC testing, treatment can be initiated immediately, leading to better patient outcomes. In cases of infectious diseases, early treatment can reduce the severity of illness and prevent complications. POC testing facilitates comprehensive patient care at the bedside, reducing the need for patients to be transported within the facility for testing. This is particularly important for critically ill patients who may have limited mobility. POC testing helps optimize the use of healthcare resources by reducing the need for additional tests, consultations, and procedures. This can lead to cost savings and improved healthcare efficiency. In emergency situations, POC testing provides crucial diagnostic information quickly, enabling healthcare providers to make informed decisions and prioritize patient care.


Download Free Sample Report

Key Market Challenges

Competition from other diagnostic tests

Syndromic testing competes with other diagnostic tests, such as molecular diagnostics and serological diagnostics. These tests may be more accurate and can provide more information about the underlying cause of the syndrome. molecular diagnostics can identify the specific pathogen causing the syndrome, while serological diagnostics can detect the presence of antibodies to the pathogen. This information can be helpful in making a diagnosis and determining the best course of treatment. Healthcare providers may be more accustomed to using traditional diagnostic methods that they are already familiar with, which can lead to a resistance to adopting newer syndromic testing approaches. Diagnostic methods that have a long history of use and established reliability may be favored by healthcare professionals, making it difficult for syndromic testing to gain traction.

Quality control and standardization

Quality control and standardization are significant challenges in the global acute care syndromic testing market. Ensuring consistent and accurate results across different syndromic testing platforms and assays is essential for the reliability and reproducibility of diagnostic outcomes. Syndromic testing platforms may use different technologies, chemistries, and reagents, leading to variability in assay performance. Differences in sensitivity, specificity, and limit of detection can impact the accuracy and reliability of test results. Syndromic testing may be performed in various laboratory settings, including clinical laboratories, hospitals, and point-of-care facilities. Inter-laboratory variability in testing procedures, equipment, and personnel expertise can affect result consistency. Syndromic testing assays targeting multiple pathogens simultaneously need to minimize cross-reactivity or interference between different targets. Cross-reactivity can lead to false-positive or false-negative results.

Integration with healthcare systems

Integration with healthcare systems poses a significant challenge to the global acute care syndromic testing market. The seamless integration of syndromic testing technologies into existing healthcare systems and workflows is essential for maximizing their benefits and widespread adoption. Syndromic testing platforms need to be compatible with existing healthcare information systems, electronic health records (EHRs), and laboratory information management systems (LIMS). Ensuring smooth data exchange and interoperability can be technically demanding. Syndromic testing generates a substantial amount of data that needs to be managed, stored securely, and accessed by relevant healthcare professionals. Establishing robust data management and connectivity solutions is crucial. Developing user-friendly interfaces that allow healthcare providers to easily access and interpret syndromic testing results within their existing workflow can be complex. User interface design needs to consider usability and efficiency. Healthcare personnel, including clinicians, laboratory technicians, and IT staff, require training to effectively use and integrate syndromic testing technologies. Training programs need to be comprehensive and ongoing. Integrating new technologies often requires changes to established clinical and laboratory workflows. Overcoming resistance to change and ensuring a smooth transition are essential for successful integration.

Key Market Trends

Rise of Point-of-Care-Testing (POCT)

The rise of Point-of-Care Testing (POCT) is a significant trend in the global Acute Care Syndromic Testing Market. Point-of-Care Testing refers to diagnostic testing performed at or near the patient's location, providing rapid results that can guide immediate clinical decision-making. POCT allows healthcare providers to quickly diagnose and initiate treatment plans, particularly in acute care settings where time is critical. Acute care syndromic testing, when adapted to POCT platforms, enables rapid identification of pathogens responsible for acute symptoms, leading to more timely and appropriate interventions. Syndromic testing conducted at the point of care eliminates the need to send samples to centralized laboratories, reducing turnaround times for results. This speed is essential in managing acute conditions and outbreaks, where rapid decisions are crucial. Point-of-care syndromic testing empowers healthcare providers to make informed decisions at the bedside. Immediate results help guide isolation measures, treatment choices, and patient management strategies, improving overall care. In situations such as infectious disease outbreaks, POCT-based acute care syndromic testing can contribute to rapid containment by quickly identifying cases and implementing appropriate control measures to prevent further spread. POCT helps optimize resource allocation by avoiding unnecessary transfers, repeat tests, and prolonged hospital stays. This efficiency is especially relevant in acute care scenarios where resources may be limited. During events like large gatherings or disaster response, point-of-care syndromic testing can provide rapid screening for infectious diseases, aiding in quick identification and management of potential outbreaks. POCT can be particularly valuable in remote or underserved regions with limited access to central laboratories. Acute care syndromic testing at the point of care bridges the gap in diagnostic capabilities.  Real-time Surveillance: Point-of-care syndromic testing generates data that can be analyzed in real time, contributing to disease surveillance efforts, early detection of emerging pathogens, and timely public health responses.

Segmental Insights

Disease Type Insights

In 2022, the Acute Care Syndromic Testing Market was dominated by the Respiratory Diseases Segment and is predicted to continue expanding over the coming years. This is due to Respiratory diseases are one of the leading causes of death worldwide. According to the World Health Organization (WHO), respiratory diseases caused an estimated 4.1 million deaths in 2019. Respiratory diseases can often have a rapid onset, making it difficult to diagnose and treat. Syndromic testing can help to identify the underlying cause of the disease and to initiate treatment early. Respiratory diseases often share similar symptoms, such as cough, fever, and shortness of breath. Acute care syndromic testing can help distinguish between different respiratory pathogens and guide appropriate treatment strategies. Respiratory diseases have significant public health implications due to their potential for rapid transmission and widespread impact. Acute care syndromic testing aids in effective outbreak management and containment. The segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.

Target Insights

In 2022, the Acute Care Syndromic Testing Markets market was dominated by Bacteria Segment and is predicted to continue expanding over the coming years. Bacteria are simple cells that have a control center containing genetic information. The DNA is in one loop. Bacteria can cause a variety of infections that affect both humans and animals. Infections can occur in the skin, in the brain, in the lungs, in the blood, or in any other part of the body. As the bacteria multiply, the infection area increases. Bacterial infections can often have a rapid onset, making them difficult to diagnose and treat. Syndromic testing can help to identify the underlying cause of the infection and to initiate treatment early. Bacterial infections can be contagious, so it is important to diagnose them quickly in order to prevent the spread of disease. Syndromic testing can provide rapid results, which can help to improve patient outcomes.

Sample Insight

In 2022, the Acute Care Syndromic Testing Markets market was dominated by Swabs Segment and is predicted to continue expanding over the coming years. Nasopharyngeal swabs are particularly effective in collecting samples from the upper respiratory tract, where many respiratory pathogens, including viruses like influenza and coronaviruses, are commonly found. Nasopharyngeal swabs offer direct access to the nasopharynx, which is often the initial site of infection for many respiratory viruses. This proximity enhances the sensitivity of detection for these pathogens.

End-User Insight

In 2022, the Acute Care Syndromic Testing Markets market was dominated by Hospital Segment and is predicted to continue expanding over the coming years. Hospitals are often the primary locations for managing acute medical conditions, emergencies, and outbreaks. Syndromic testing is particularly valuable in this environment to quickly diagnose and manage patients with urgent health needs. Hospitals serve a diverse and often high-volume patient population, making them a key setting for syndromic testing. The ability to rapidly diagnose a wide range of pathogens is crucial for effective patient care and infection control. Hospital emergency departments handle a significant number of acute cases. Syndromic testing supports rapid triage and decision-making in emergency situations, enabling timely interventions.


Download Free Sample Report

Regional Insights

The North America region has established itself as the leader in the Global Acute Care Syndromic Testing Markets Market. North America, particularly the United States and Canada, boasts a well-developed and advanced healthcare infrastructure. This infrastructure supports the rapid adoption and integration of innovative diagnostic technologies like acute care syndromic testing. The region is a hub for technological innovation and research in healthcare. This fosters the development of cutting-edge syndromic testing platforms and solutions.

Recent Developments

  • In May 2023, Hologic Inc., announced that it has been granted 510 (k) clearance by the United States FDA for the development and commercialization of Panther Fusion®, the first molecular diagnostic test for the detection of the four most common respiratory viruses: Severe Acute Respiratory Syndrome CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV).
  • In April 2023, CLIMADE is a consortium of over 100 scientists from academia and public health organizations around the world who work to reduce the risk of future disease epidemics. Abbott Laboratories has partnered with CLIMADE to leverage diagnostic testing and advanced data science technologies.
  • In April 2023, QIAGEN, the world’s leading diagnostics company, today announced the commercial launch of its Japanese-based syndromic testing system, QIAstat-Ds, which is capable of detecting over 20 respiratory pathogens from a single sample, including the highly transmissible coronavirus (SARS)-CoV-2.

Key Market Players

·              Abbott Laboratories

·              Becton, Dickinson and Company

·              Biocartis NV

·              bioMerieux SA (BioFire Diagnostics)

·              Danaher Corporation (Cepheid, Inc.)

·              DiaSorin S.p.A (Luminex Corporation)

·              Eurofins Scientific (Eurofins Viracor)

·              Hologic Inc.

·              Laboratory Corporation of America Holdings.

·              QIAGEN N.V.

·              QuantuMDx Group Ltd

 By Disease Type

  By Target

By Region

 By Sample Type

 By End User

•       Respiratory Disease

•       Gastrointestinal Diseases

•       Genitourinary Diseases

•       Tropical Disease

•       Others

•       Bacteria

•       Viruses

•       Fungi

•       Parasites

•       Asia Pacific

•       North America

•       Europe

•       Middle East & Africa

•       South America

•       Blood

•       Urine

•       Biofluids

•       Stool

•       Swabs

•       Others

•       Hospitals

•       Clinical & Diagnostics Laboratories

•       Research & Academic Institutions

•       Others

 

Report Scope:

In this report, the Global Acute Care Syndromic Testing Markets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Acute Care Syndromic Testing Market, By Disease Type:

o   Respiratory Diseases

o   Gastrointestinal Diseases

o   Genitourinary Diseases

o   Tropical Diseases

o   Others

  • Acute Care Syndromic Testing Market, By Target:

o   Bacteria

o   Fungi

o   Viruses

o   Parasites

  • Acute Care Syndromic Testing Market, By Sample Type:

o   Blood

o   Urine

o   Biofluids

o   Stool

o   Swabs

o   Others

  • Acute Care Syndromic Testing Market, By End User:

o   Hospitals

o   Clinical & Diagnostics Laboratories

o   Research & Academic Institutions

o   Others

  • Global Acute Care Syndromic Testing Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles:ajor companies present in the Global Acute Care Syndromic Testing Market.

Available Customizations:

Global Acute Care Syndromic Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Acute Care Syndromic Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Acute Care Syndromic Testing Market Outlook

5.1.  Market Size & Forecast

5.1.1.  By Value

5.2.  Market Share & Forecast

5.2.1.  By Disease Type (Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Others)

5.2.2.  By Target (Bacteria, Viruses, Fungi, Parasites)

5.2.3.  By Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others)

5.2.4.  By End User (Hospitals, Clinical & Diagnostics Laboratories, Research & Academic Institutions, Others)

5.2.5.  By Company (2022)

5.2.6.  By Region

5.3.  Market Map

6.    North America Acute Care Syndromic Testing Market Outlook

6.1.  Market Size & Forecast       

6.1.1.  By Value

6.2.  Market Share & Forecast

6.2.1.  By Disease Type

6.2.2.  By Target

6.2.3.  By Sample Type

6.2.4.  By End User

6.2.5.  By Country

6.3.  North America: Country Analysis

6.3.1.  United States Acute Care Syndromic Testing Market Outlook

6.3.1.1.                Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.                Market Share & Forecast

6.3.1.2.1.             By Disease Type

6.3.1.2.2.             By Target

6.3.1.2.3.             By Sample Type

6.3.1.2.4.             By End User

6.3.2.  Mexico Acute Care Syndromic Testing Market Outlook

6.3.2.1.                Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.                Market Share & Forecast

6.3.2.2.1.             By Disease Type

6.3.2.2.2.             By Target

6.3.2.2.3.             By Sample Type

6.3.2.2.4.             By End User

6.3.3.  Canada Acute Care Syndromic Testing Market Outlook

6.3.3.1.                Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.                Market Share & Forecast

6.3.3.2.1.             By Disease Type

6.3.3.2.2.             By Target

6.3.3.2.3.             By Sample Type

6.3.3.2.4.             By End User

7.    Europe Acute Care Syndromic Testing Market Outlook

7.1.  Market Size & Forecast       

7.1.1.  By Value

7.2.  Market Share & Forecast

7.2.1.  By Disease Type

7.2.2.  By Target 

7.2.3.  By Sample Type

7.2.4.  By End User

7.2.5.  By Country

7.3.  Europe: Country Analysis

7.3.1.  France Acute Care Syndromic Testing Market Outlook

7.3.1.1.                Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.                Market Share & Forecast

7.3.1.2.1.             By Disease Type

7.3.1.2.2.             By Target

7.3.1.2.3.             By Sample Type

7.3.1.2.4.             By End User

7.3.2.  Germany Acute Care Syndromic Testing Market Outlook

7.3.2.1.                Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.                Market Share & Forecast

7.3.2.2.1.             By Disease Type

7.3.2.2.2.             By Target

7.3.2.2.3.             By Sample Type

7.3.2.2.4.             By End User

7.3.3.  United Kingdom Acute Care Syndromic Testing Market Outlook

7.3.3.1.                Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.                Market Share & Forecast

7.3.3.2.1.             By Disease Type

7.3.3.2.2.             By Target

7.3.3.2.3.             By Sample Type

7.3.3.2.4.             By End User

7.3.4.  Italy Acute Care Syndromic Testing Market Outlook

7.3.4.1.                Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.                Market Share & Forecast

7.3.4.2.1.             By Disease Type

7.3.4.2.2.             By Target

7.3.4.2.3.             By Sample Type

7.3.4.2.4.             By End User

7.3.5.  Spain Acute Care Syndromic Testing Market Outlook

7.3.5.1.                Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.                Market Share & Forecast

7.3.5.2.1.             By Disease Type

7.3.5.2.2.             By Target

7.3.5.2.3.             By Sample Type

7.3.5.2.4.             By End User

8.    Asia-Pacific Acute Care Syndromic Testing Market Outlook

8.1.  Market Size & Forecast       

8.1.1.  By Value

8.2.  Market Share & Forecast

8.2.1.  By Disease Type

8.2.2.  By Target 

8.2.3.  By Sample Type

8.2.4.  By End User

8.2.5.  By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.  China Acute Care Syndromic Testing Market Outlook

8.3.1.1.                Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.                Market Share & Forecast

8.3.1.2.1.             By Disease Type

8.3.1.2.2.             By Target

8.3.1.2.3.             By Sample Type

8.3.1.2.4.             By End User

8.3.2.  India Acute Care Syndromic Testing Market Outlook

8.3.2.1.                Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.                Market Share & Forecast

8.3.2.2.1.             By Disease Type

8.3.2.2.2.             By Target

8.3.2.2.3.             By Sample Type

8.3.2.2.4.             By End User

8.3.3.  South Korea Acute Care Syndromic Testing Market Outlook

8.3.3.1.                Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.                Market Share & Forecast

8.3.3.2.1.             By Disease Type

8.3.3.2.2.             By Target

8.3.3.2.3.             By Sample Type

8.3.3.2.4.             By End User

8.3.4.  Japan Acute Care Syndromic Testing Market Outlook

8.3.4.1.                Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.                Market Share & Forecast

8.3.4.2.1.             By Disease Type

8.3.4.2.2.             By Target

8.3.4.2.3.             By Sample Type

8.3.4.2.4.             By End User

8.3.5.  Australia Acute Care Syndromic Testing Market Outlook

8.3.5.1.                Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.                Market Share & Forecast

8.3.5.2.1.             By Disease Type

8.3.5.2.2.             By Target

8.3.5.2.3.             By Sample Type

8.3.5.2.4.             By End User

9.    South America Acute Care Syndromic Testing Market Outlook

9.1.  Market Size & Forecast       

9.1.1.  By Value

9.2.  Market Share & Forecast

9.2.1.  By Disease Type

9.2.2.  By Target

9.2.3.  By Sample Type

9.2.4.  By End User 

9.2.5.  By Country

9.3.  South America: Country Analysis

9.3.1.  Brazil Acute Care Syndromic Testing Market Outlook

9.3.1.1.                Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.                Market Share & Forecast

9.3.1.2.1.             By Disease Type

9.3.1.2.2.             By Target

9.3.1.2.3.             By Sample Type

9.3.1.2.4.             By End User

9.3.2.  Argentina Acute Care Syndromic Testing Market Outlook

9.3.2.1.                Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.                Market Share & Forecast

9.3.2.2.1.             By Disease Type

9.3.2.2.2.             By Target

9.3.2.2.3.             By Sample Type

9.3.2.2.4.             By End User

9.3.3.  Colombia Acute Care Syndromic Testing Market Outlook

9.3.3.1.                Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.                Market Share & Forecast

9.3.3.2.1.             By Disease Type

9.3.3.2.2.             By Target

9.3.3.2.3.             By Sample Type

9.3.3.2.4.             By End User

10. Middle East and Africa Acute Care Syndromic Testing Market Outlook

10.1.             Market Size & Forecast        

10.1.1.               By Value

10.2.             Market Share & Forecast

10.2.1.               By Disease Type

10.2.2.               By Target

10.2.3.               By Sample Type

10.2.4.               By End User 

10.2.5.               By Country

10.3.             MEA: Country Analysis

10.3.1.               South Africa Acute Care Syndromic Testing Market Outlook

10.3.1.1.             Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.             Market Share & Forecast

10.3.1.2.1.           By Disease Type

10.3.1.2.2.           By Target

10.3.1.2.3.           By Sample Type

10.3.1.2.4.           By End User

10.3.2.               Saudi Arabia Acute Care Syndromic Testing Market Outlook

10.3.2.1.             Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.             Market Share & Forecast

10.3.2.2.1.           By Disease Type

10.3.2.2.2.           By Target

10.3.2.2.3.           By Sample Type

10.3.2.2.4.           By End User

10.3.3.               UAE Acute Care Syndromic Testing Market Outlook

10.3.3.1.             Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.             Market Share & Forecast

10.3.3.2.1.           By Disease Type

10.3.3.2.2.           By Target

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. PESTLE Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. Competitive Landscape

15.1.             Business Overview

15.2.             Company Snapshot

15.3.             Products & Services

15.4.             Financials (In case of listed companies)

15.5.             Recent Developments

15.6.             SWOT Analysis

15.6.1. Abbott Laboratories

15.6.2. Becton, Dickinson and Company

15.6.3. Biocartis NV

15.6.4. bioMerieux SA (BioFire Diagnostics)

15.6.5. Danaher Corporation (Cepheid, Inc.)

15.6.6. DiaSorin S.p.A (Luminex Corporation)

15.6.7. Eurofins Scientific (Eurofins Viracor)

15.6.8. Karius

15.6.9. Laboratory Corporation of America Holdings.

15.6.10.              QIAGEN N.V.

15.6.11.              QuantuMDx Group Ltd.

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Acute Care Syndromic Testing Market was estimated to be USD 2.89 Billion in 2022.

down-arrow

Abbott Laboratories, Becton, Dickinson and Company, Biocartis NV, bioMerieux SA (BioFire Diagnostics), Danaher Corporation (Cepheid, Inc.), DiaSorin S.p.A (Luminex Corporation), Eurofins Scientific (Eurofins Viracor), Karius, Laboratory Corporation of America Holdings., QIAGEN N.V., QuantuMDx Group Ltd are some of the key players operating in the Global Acute Care Syndromic Testing Market.

down-arrow

Quality control & Standard and Competition from other diagnostic tests are the major challenges faced by the Global Acute Care Syndromic Testing Market in the upcoming years.

down-arrow

Rise in Infectious Disease Outbreak and increasing demand for timely diagnosis is majorly driving the demand for the global Acute Care Syndromic Testing Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Acute Care Syndromic Testing Market to grow with a CAGR of 5.56% through 2028

Nov, 2023

The rising prevalence of infectious diseases and initiatives taken by the government to support syndromic testing programs are the major drivers for the Global Acute Care Syndromic Testing Market.

Why Choose Us